{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:23:12Z","timestamp":1793013792265,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/inf.0000000000001340","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T11:16:07Z","timestamp":1474370167000},"page":"2-8","source":"Crossref","is-referenced-by-count":29,"title":["Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy"],"prefix":"10.1097","volume":"36","author":[{"given":"Paolo","family":"Manzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosco","family":"Paes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Dall\u2019Agnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Maule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Harimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1874285801105010135","article-title":"Epidemiology of respiratory syncytial virus infection in preterm infants.","volume":"5","author":"Resch","year":"2011","journal-title":"Open Microbiol J"},{"key":"R2-3-20210202","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(15)00255-6","article-title":"Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics.","volume":"3","author":"Mazur","year":"2015","journal-title":"Lancet Respir Med"},{"key":"R3-3-20210202","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"R4-3-20210202","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1824-7288-40-65","article-title":"Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants.","volume":"40","author":"Baraldi","year":"2014","journal-title":"Ital J Pediatr"},{"key":"R5-3-20210202","first-page":"199.e1","article-title":"Comit\u00e9 de Est\u00e1ndares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections.","volume":"82","author":"FiguerasAloy","year":"2015","journal-title":"AnPediatr (Barc"},{"key":"R6-3-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection.","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr Child Health"},{"key":"R7-3-20210202","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0378-3782(12)70012-9","article-title":"High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.","volume":"88(suppl 2)","author":"Manzoni","year":"2012","journal-title":"Early Hum Dev"},{"key":"R8-3-20210202","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00431-011-1654-8","article-title":"Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.","volume":"171","author":"Paes","year":"2012","journal-title":"Eur J Pediatr"},{"key":"R9-3-20210202","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/INF.0b013e31821146f7","article-title":"CARESS: the Canadian registry of palivizumab.","volume":"30","author":"Mitchell","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R10-3-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13052-015-0203-x","article-title":"Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).","volume":"41","author":"Bollani","year":"2015","journal-title":"Ital J Pediatr"},{"key":"R12-3-20210202","doi-asserted-by":"crossref","first-page":"e0134711","DOI":"10.1371\/journal.pone.0134711","article-title":"Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for respiratory syncytial virus prevention.","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"R13-3-20210202","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management.","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"R14-3-20210202","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1542\/peds.2005-0620I","article-title":"Summary proceedings from the bronchopulmonary dysplasia group.","volume":"117","author":"Walsh","year":"2006","journal-title":"Pediatrics"},{"key":"R15-3-20210202","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr Res"},{"key":"R16-3-20210202","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1542\/peds.2013-3916","article-title":"Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.","volume":"133","author":"Yi","year":"2014","journal-title":"Pediatrics"},{"key":"R17-3-20210202","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-3-20210202","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pupt.2013.03.007","article-title":"Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.","volume":"26","author":"La Via","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"R19-3-20210202","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1542\/peds.2004-0226","article-title":"Palivizumab use in very premature infants in the neonatal intensive care unit.","volume":"114","author":"Wu","year":"2004","journal-title":"Pediatrics"},{"key":"R20-3-20210202","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","article-title":"Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV.","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R21-3-20210202","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R22-3-20210202","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0378-3782(12)70009-9","article-title":"What is BPD in 2012 and what will BPD become?","volume":"88 Suppl 2","author":"Jobe","year":"2012","journal-title":"Early Hum Dev"},{"key":"R23-3-20210202","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1542\/peds.2004-2865","article-title":"Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do.","volume":"115","author":"Manzoni","year":"2005","journal-title":"Pediatrics"},{"key":"R24-3-20210202","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ppul.10288","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.","volume":"35","author":"Parnes","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"R25-3-20210202","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/jp.2008.28","article-title":"Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.","volume":"28","author":"Frogel","year":"2008","journal-title":"J Perinatol"},{"key":"R27-3-20210202","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","article-title":"Committee on Infectious Disease. Policy statementsmodified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.","volume":"124","year":"2009","journal-title":"Pediatrics"},{"key":"R28-3-20210202","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4161\/hv.27426","article-title":"Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.","volume":"10","author":"Makari","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R29-3-20210202","doi-asserted-by":"crossref","first-page":"917068","DOI":"10.1155\/2013\/917068","article-title":"Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.","volume":"2013","author":"Paes","year":"2013","journal-title":"Clin Dev Immunol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:27Z","timestamp":1620954747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201701000-00003"}},"subtitle":["An International, Prospective Cohort Study"],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001340","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}